.png){kind=icon}
.png){kind=icon}
Return
Unveiling trends: insights into medicines reimbursement recommendations and health technology management in Ireland (2018–2023)
.png){kind=icon}
OA
AI
D
C
M
P
P
S
DOI：10.1017/S0266462326103717.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
ObjectivesHealth technology management (HTM) involves systems designed to ensure the safe; effective; and cost-effective use of health technologies following reimbursement. This study examines the recommendations of Ireland’s Health Service Executive-Drugs Group (HSE-DG); exploring the characteristics and patterns of positive or conditional positive recommendations and HTM-related requirements.MethodsWe reviewed the minutes of HSE-DG meetings between January 2018 and December 2023. Data on medicines reviewed during this period were extracted into Microsoft Excel and analyzed narratively.ResultsOver the study period; the HSE-DG reviewed 192 medicines (including new medicines and new indications for existing medicines); of which 157 received positive (115) or conditional positive recommendations (42). Of these; thirty-three were subject to HTM conditions; typically involving a managed access protocol or a specific reimbursement application process. Due to inconsistent reporting of key information; quantitative analysis was not feasible. However; common characteristics among HTM-linked recommendations emerged. These included submissions for reimbursement targeting a subset of the licensed population (45.5 percent vs. 5.6 percent in non-HTM cases); designation as orphan medicines (39.4 percent vs. 29.8 percent); and having both first-in-class and new chemical entity designations (75.8 percent vs. 47.6 percent).ConclusionsFindings indicate an increasing trend toward positive/conditional positive reimbursement recommendations with HTM in the Irish setting; with an average of 21 percent of positive/conditional positive recommendations over the study period contingent on HTM. More granular and consistent reporting of key indicators would enable the determination of characteristics associated with reimbursement recommendations with HTM.
Keywords:
health technology assessment
reimbursement
orphan drugs
health technology management
managed access protocols
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
I
IF:
3.1
Papers:
167
Citations:
0
Organization
Cited Papers